Hugan tablets for the treatment of RUCAM based drug-induced liver injury: a propensity score matching analysis using a nationwide database
| Autor: | Xiaorong Xu, Xiaoyun Li, Jianzhong Zhang, Xian Han, Jie Zhou, Shilin Qu, Hafiz Khuram Raza, Yimin Mao, Weidong Fang, Jing Li, Feng Jin |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Drug
Liver injury medicine.medical_specialty Databases Factual business.industry media_common.quotation_subject Nationwide database General Medicine medicine.disease Internal medicine Propensity score matching medicine Humans Pharmacology (medical) General Pharmacology Toxicology and Pharmaceutics Chemical and Drug Induced Liver Injury business Propensity Score media_common Drugs Chinese Herbal Tablets |
| Zdroj: | Expert review of clinical pharmacology. 14(12) |
| ISSN: | 1751-2441 |
| Popis: | Drug-induced liver injury (DILI) is a major clinical challenge with no specific therapeutic drugs available. It is crucial to develop new agents to improve the clinical outcome of patients with DILI. This study evaluated the efficacy and safety of Hugan tablets in DILI patients using a nationwide database.We analyzed the clinical data of DILI patients from a nationwide DILI database (www.hepatox.org). Patients who received oral Hugan tablets for DILI were defined as the Hugan group, and those who received no treatment for DILI were defined as the control group.There were 111 cases in the Hugan group and 512 cases in the control group. One-to-one propensity score matching created 111 matched pairs. The normalization rates of alanine aminotransferase and aspartate aminotransferase in the Hugan group were significantly higher than those in the control group (50.45% vs. 26.13%, p ≤ .0002 and 67.57% vs. 41.75%, p ≤ .0001). There were no differences in the incidence of renal function impairment or blood abnormality between the two groups.Hugan tablets are safe and effective in DILI treatment. Large-scale randomized controlled studies are needed to explore the effects of Hugan tablets on DILI induced by different offending drugs.The study protocol was posted on ClinicalTrials.gov with NCT number: NCT02407964. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|